IntoCell, Inc. (KOSDAQ:287840)

South Korea flag South Korea · Delayed Price · Currency is KRW
24,400
+900 (3.83%)
At close: Aug 4, 2025, 3:30 PM KST
3.83%
Market Cap362.28B
Revenue (ttm)2.95B
Net Income (ttm)-8.95B
Shares Out14.85M
EPS (ttm)-679.25
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume98,935
Average Volume421,848
Open23,600
Previous Close23,500
Day's Range23,150 - 24,600
52-Week Range17,000 - 52,400
Betan/a
RSI40.58
Earnings Daten/a

About United States Steel

IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxi... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 287840
Full Company Profile

Financial Performance

In 2024, IntoCell's revenue was 2.91 billion, an increase of 79.72% compared to the previous year's 1.62 billion. Losses were -9.91 billion, -40.91% less than in 2023.

Financial Statements

News

There is no news available yet.